MedTrace Logo

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

NCT02631057 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4313

Last updated 2018-03-30

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare the Length of Stay from treatment of oral anticoagulant initiation to hospital discharge of patients hospitalized and subsequently treated with dabigatran or warfarin for non-valvular atrial fibrillation in a real-world Japanese clinical practice. The secondary objective of the study is to compare LoS of patients hospitalized with 1) acute ischemic stroke, and 2) due to non-valvular atrial fibrillation. Other objectives are (1) to compare the in-hospital direct and indirect-related costs between dabigatran and warfarin, and (2) to compare the rates of patients directly discharged at home after the index hospitalization between dabigatran and warfarin.

Conditions

Interventions

DRUG

Dabigatran

Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day

DRUG

Warfarin

Warfarin tablet (adjustment by each patients)

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2016-09-07
Completion
2016-09-07

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631057 on ClinicalTrials.gov